ClinicalTrials.gg
CompletedNCT04774380LUMINANCEUpdated May 23, 2025Results posted

Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer

A Phase 3 interventional study of Durvalumab and Cisplatin in Extensive-stage Small Cell Lung Cancer, sponsored by AstraZeneca. Completed at 35 sites in 6 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2025-05-23.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
152
Allocation
Non-randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing durvalumab in Small Cell Lung Carcinoma — 10 open to participants now, 19 under way, 3 of them phase 3. durvalumab · Small Cell Lung Carcinoma.

Enrollment
5th of 36
152 · median 50
Started
2021
with 6 others
Phase 3
6 of 36
none open now
Registered
15th of 36
by date
Lead sponsor
12 of 36
AstraZeneca

Among the 36 studies testing durvalumab in Small Cell Lung Carcinoma, this one is the 5th largest by enrollment, is one of 7 that started in 2021, is one of 6 in phase 3, and was the 15th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

10 of the 36 studies testing durvalumab in Small Cell Lung Carcinoma are open now, in 8 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing durvalumab in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

Study to determine the safety and tolerability profile of durvalumab with platinum (cisplatin or carboplatin) plus etoposide (EP) as first-line treatment in participants with extensive-stage small-cell lung cancer.

Read the detailed description

The study will be conducted in North America, Europe and Turkey.

In this single arm study participants will be treated with with durvalumab alone and concurrently with platinum-based chemotherapy and etoposide during the study period until radiological disease progression, unless there is clinical progression, unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met, as per investigator assessment.

03

Conditions studied

  • Extensive-stage Small Cell Lung Cancer

Keywords

  • Chemotherapy
  • Aggressive malignancy
  • Programmed cell death ligand-1
  • Platinum-based chemotherapy
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • - or cytologically-documented ES-SCLC (stage IV [T any, N any, M1 a/b], or with T3-4 due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan (; must be asymptomatic or treated and stable off and anticonvulsants for at least 1 month prior to study treatment)
  • Participants must be considered suitable to receive a platinum-based chemotherapy regimen as treatment for the ES-SCLC. Chemotherapy must contain either cisplatin or carboplatin in combination with etoposide
  • World Health Organization/ performance status of 0 to 2 at enrollment Baseline computed tomography/ magnetic resonance imaging results of the brain, chest and abdomen (including liver and adrenal glands) within 28 days prior to the treatment initiation
  • No prior exposure to immune-mediated therapy including, but not limited to, other anti- , anti-Programmed cell death-1 (PD-1), anti- Programmed cell death ligand-1 (PD-L1), and anti-PD-L2 (anti-PD-L2) antibodies, excluding therapeutic anticancer vaccines
  • Adequate organ and marrow function
  • Body weight > 30 kg
  • Evidence of status or negative urinary or serum pregnancy test for female pre-menopausal participants

Exclusion criteria

Exclusion Criteria:

  • History of allogeneic organ transplantation
  • Active or prior documented or inflammatory disorders, systemic lupus erythematosus, sarcoidosis syndrome, or wegener syndrome
  • Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, active interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the participant to give written
  • History of another primary except for:

    • Malignancy treated with curative intent and with no known active disease ≥ 5 years before the first dose of medicinal product (IMP) and of low potential risk for recurrence
    • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
    • Adequately treated carcinoma in situ without evidence of disease
  • History of and active primary immunodeficiency
  • Active infection including tuberculosis, , ,
  • Any unresolved toxicity Grade ≥ 2 from previous anticancer therapy
  • Known allergy or to any of the study drugs or any of the study drug
  • Received prior systemic therapy for ES-SCLC
  • Medical to platinum (cisplatin or carboplatin)-etoposide-based chemotherapy
  • Any concurrent chemotherapy, IMP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions is acceptable
  • Planned consolidation chest radiation therapy. Radiation therapy outside of the chest for palliative care is allowed but must be completed before first dose of the study medication
  • Receipt of within 30 days prior to the first dose of in IMP
  • Major surgical procedure within 28 days prior to the first dose of IMP
  • Participants who have received prior immunotherapy agents including or anti PD-L1
  • Current or prior use of medication within 14 days before the first dose of durvalumab
  • Participation in another clinical study with an investigational product administered in the last 4 weeks
  • Female participants who are pregnant or breastfeeding or male or female participants of who are not willing to employ effective from screening to 90 days after the last dose of durvalumab and 180 days after the last dose of etoposide
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
152 participants (actual)

Study arms

  • Experimental
    Durvalumab - (cisplatin or carboplatin) - Etoposide

    Participants will receive durvalumab dose A administered via intravenous (IV) infusion concurrently with platinum-based chemotherapy and etoposide every 3 weeks (q3w). Thereafter, durvalumab monotherapy will be continued every 4 weeks post-chemotherapy unless specific treatment discontinuation criteria are met.

    Drug: Durvalumab · Drug: Cisplatin · Drug: Carboplatin · Drug: Etoposide

Interventions

  • Participants will receive durvalumab via IV infusion on Day 1 of each cycle.

  • Participants will receive cisplatin via IV administration on Day 1 of each cycle.

  • Participants will receive carboplatin via IV administration Day 1 of each cycle.

  • Participants will receive etoposide via IV administration on days 1 to 3 of each cycle.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Incidence of Grade 3 or Higher Adverse Events (AEs)

    Incidence of Grade 3 or higher adverse events to evaluate safety and tolerability profile of durvalumab + Platinum (cisplatin or carboplatin) plus etoposide (EP) treatment was assessed.

    Time frame: From first dose of study treatment until 90 days after treatment discontinuation, up to 2.5 years.

  2. Number of Participants With Incidence of Immune Mediated Adverse Events (imAEs)

    Immune mediated adverse events (imAEs) were assessed to evaluate safety and tolerability profile of durvalumab + EP treatment. An imAE is defined as an AESI that is associated with drug exposure and is consistent with an immune-mediated mechanism of action (MOA) and where there is no clear alternate etiology.

    Time frame: From first dose of study treatment until 90 days after treatment discontinuation, up to 2.5 years.

Secondary outcomes

  1. Progression-free Survival (PFS)

    Efficacy of durvalumab + EP treatment by evaluating PFS according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) was assessed. The PFS is the time from the first date of treatment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from Investigational medicinal product (IMP) or received another anticancer therapy prior to progression.

    Time frame: From first dose of study treatment until disease progression or death, up to 2.5 years.

  2. Percentage of Participants Alive and Progression-free at 12 Months From First Date of Treatment (PFS12)

    The efficacy of durvalumab + EP treatment by evaluating PFS12 according to RECIST 1.1 was assessed.

    Time frame: From first date of study treatment until 12 months.

  3. Objective Response Rate (ORR)

    The efficacy of durvalumab + EP treatment by evaluating ORR according to RECIST 1.1 was assessed. The ORR will be assessed based on Investigator-assessed response to treatment of complete response (CR) and partial response (PR), per RECIST1.1.

    Time frame: From screening until disease progression or the last evaluable assessment in the absence of progression, up to 2.5 years.

  4. Duration of Response (DoR)

    The efficacy of durvalumab + EP treatment by evaluating DoR according to RECIST 1.1 was assessed. The DoR is time from the date of first documented response per RECIST1.1 until the first date of documented progression per RECIST1.1 or death in the absence of disease progression.

    Time frame: From the date of first documented response until the first date of documented progression or death in the absence of disease progression, up to 2.5 years.

  5. Percentage of Participants Remaining in Response, 12 Months After First Documented Objective Response (DoR12)

    The efficacy of durvalumab + EP treatment by evaluating DoR12 according to RECIST 1.1 was assessed.

    Time frame: From the date of first documented response until the first date of documented progression or death in the absence of disease progression, up to 2.5 years.

  6. Overall Survival (OS)

    Assessment of the efficacy of durvalumab + EP treatment by evaluating OS. The OS is the time from the first date of treatment until death due to any cause.

    Time frame: From first dose of study treatment to death, up to 2.5 years.

  7. Percentage of Participants Alive at 12 Months From First Date of Treatment (OS12)

    The efficacy of durvalumab + EP treatment by evaluating OS12 was assessed.

    Time frame: From first dose of study treatment till 12 months.

  8. Number of Participants With Adverse Events and Serious Adverse Events

    To evaluate safety and tolerability profile of durvalumab + EP treatment, adverse events and serious adverse events were assessed.

    Time frame: From first dose of study treatment until 90 days after discontinuation, up to 2.5 years.

  9. Number of Participants With Adverse Events of Special Interests

    To evaluate safety and tolerability profile of durvalumab + EP treatment, adverse events of special interests were assessed. An AESI is an AE of scientific and medical interest specific to understanding of the IMP. AESIs for durvalumab include, but are not limited to, events with a potential inflammatory or immune-mediated mechanism and which may require more frequent monitoring and/or interventions such as steroids, immunosuppressants, and/or hormone replacement therapy. This includes adverse events of special/ possible interest.

    Time frame: From first dose of study treatment until 90 days after discontinuation, up to 2.5 years.

07

Results

Posted Aug 20, 2024
Limitations and caveats
The study results are presented as of the final data cut-off dated April 21, 2024. After final DCO, no additional data was collected for the purpose of the analysis. The participants were allowed to continue the study drug until other drug supply options were available. The last subject's last visit was declared once all participants were transferred to a rollover study or a marketed product, which occurred on January 2, 2025 and was reported as the study completion date.

Participant flow

The study was conducted at 32 sites in 5 countries: Bulgaria, Czech Republic, Germany, Italy, Turkey. Study results are presented as of final data cut-off (DCO), 21Apr2024. After final DCO, no additional data was collected for the purpose of the analysis. Participants were allowed to continue the study drug until other drug supply options were available. The last subject's last visit was declared on 2Jan2025 once all participants were transferred to a rollover study or marketed product.

Participant flow — Overall Study
MilestoneDurvalumab - (Cisplatin or Carboplatin) - Etoposide (Durvalumab +EP)
Started152
Completed152
Not completed0

Outcome measures

PrimaryNumber of Participants With Incidence of Grade 3 or Higher Adverse Events (AEs)

Incidence of Grade 3 or higher adverse events to evaluate safety and tolerability profile of durvalumab + Platinum (cisplatin or carboplatin) plus etoposide (EP) treatment was assessed.

Time frame:
From first dose of study treatment until 90 days after treatment discontinuation, up to 2.5 years.
Reported as:
Count of participants · Participants
Number of Participants With Incidence of Grade 3 or Higher Adverse Events (AEs)
ParticipantsDurvalumab+EP
Number of Participants With Incidence of Grade 3 or Higher Adverse Events (AEs)91
PrimaryNumber of Participants With Incidence of Immune Mediated Adverse Events (imAEs)

Immune mediated adverse events (imAEs) were assessed to evaluate safety and tolerability profile of durvalumab + EP treatment. An imAE is defined as an AESI that is associated with drug exposure and is consistent with an immune-mediated mechanism of action (MOA) and where there is no clear alternate etiology.

Time frame:
From first dose of study treatment until 90 days after treatment discontinuation, up to 2.5 years.
Reported as:
Count of participants · Participants
Number of Participants With Incidence of Immune Mediated Adverse Events (imAEs)
ParticipantsDurvalumab+EP
Number of Participants With Incidence of Immune Mediated Adverse Events (imAEs)22
SecondaryProgression-free Survival (PFS)

Efficacy of durvalumab + EP treatment by evaluating PFS according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) was assessed. The PFS is the time from the first date of treatment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from Investigational medicinal product (IMP) or received another anticancer therapy prior to progression.

Time frame:
From first dose of study treatment until disease progression or death, up to 2.5 years.
Reported as:
Median · Months
Progression-free Survival (PFS)
MonthsDurvalumab+EP
Progression-free Survival (PFS)6.3 (5.75 to 6.47)
SecondaryPercentage of Participants Alive and Progression-free at 12 Months From First Date of Treatment (PFS12)

The efficacy of durvalumab + EP treatment by evaluating PFS12 according to RECIST 1.1 was assessed.

Time frame:
From first date of study treatment until 12 months.
Reported as:
Number · Percentage of participants
Percentage of Participants Alive and Progression-free at 12 Months From First Date of Treatment (PFS12)
Percentage of participantsDurvalumab+EP
Percentage of Participants Alive and Progression-free at 12 Months From First Date of Treatment (PFS12)15.0 (9.76 to 21.21)
SecondaryObjective Response Rate (ORR)

The efficacy of durvalumab + EP treatment by evaluating ORR according to RECIST 1.1 was assessed. The ORR will be assessed based on Investigator-assessed response to treatment of complete response (CR) and partial response (PR), per RECIST1.1.

Time frame:
From screening until disease progression or the last evaluable assessment in the absence of progression, up to 2.5 years.
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR)
Percentage of participantsDurvalumab+EP
Objective Response Rate (ORR)66.4 (58.3 to 73.9)
SecondaryDuration of Response (DoR)

The efficacy of durvalumab + EP treatment by evaluating DoR according to RECIST 1.1 was assessed. The DoR is time from the date of first documented response per RECIST1.1 until the first date of documented progression per RECIST1.1 or death in the absence of disease progression.

Time frame:
From the date of first documented response until the first date of documented progression or death in the absence of disease progression, up to 2.5 years.
Reported as:
Median · Months
Duration of Response (DoR)
MonthsDurvalumab+EP
Duration of Response (DoR)5.2 (5.03 to 5.59)
SecondaryPercentage of Participants Remaining in Response, 12 Months After First Documented Objective Response (DoR12)

The efficacy of durvalumab + EP treatment by evaluating DoR12 according to RECIST 1.1 was assessed.

Time frame:
From the date of first documented response until the first date of documented progression or death in the absence of disease progression, up to 2.5 years.
Reported as:
Number · Percentage of participants
Percentage of Participants Remaining in Response, 12 Months After First Documented Objective Response (DoR12)
Percentage of participantsDurvalumab+EP
Percentage of Participants Remaining in Response, 12 Months After First Documented Objective Response (DoR12)19.8 (12.70 to 28.06)
SecondaryOverall Survival (OS)

Assessment of the efficacy of durvalumab + EP treatment by evaluating OS. The OS is the time from the first date of treatment until death due to any cause.

Time frame:
From first dose of study treatment to death, up to 2.5 years.
Reported as:
Median · Months
Overall Survival (OS)
MonthsDurvalumab+EP
Overall Survival (OS)16.4 (12.45 to 18.73)
SecondaryPercentage of Participants Alive at 12 Months From First Date of Treatment (OS12)

The efficacy of durvalumab + EP treatment by evaluating OS12 was assessed.

Time frame:
From first dose of study treatment till 12 months.
Reported as:
Number · Percentage of participants
Percentage of Participants Alive at 12 Months From First Date of Treatment (OS12)
Percentage of participantsDurvalumab+EP
Percentage of Participants Alive at 12 Months From First Date of Treatment (OS12)59.8 (51.00 to 67.55)
SecondaryNumber of Participants With Adverse Events and Serious Adverse Events

To evaluate safety and tolerability profile of durvalumab + EP treatment, adverse events and serious adverse events were assessed.

Time frame:
From first dose of study treatment until 90 days after discontinuation, up to 2.5 years.
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events and Serious Adverse Events
ParticipantsDurvalumab+EP
Any Adverse event (AE)142
Any AE possibly related to any treatment109
Any AE of maximum CTCAE grade 3 or grade 485
Any AE of maximum CTCAE grade 3 or grade 4, possibly related to any treatment59
Any AE with outcome of death15
Any AE with outcome of death, possibly related to any treatment4
Any AE with outcome of death, possibly related to durvalumab0
Any AE with outcome of death, possibly related to EP4
Any SAE (including events with outcome of death)52
Any SAE (including events with outcome of death), possibly related to any treatment16
Any AE leading to interruption or discontinuation of durvalumab40
Any AE leading to interruption or discontinuation of EP41
SecondaryNumber of Participants With Adverse Events of Special Interests

To evaluate safety and tolerability profile of durvalumab + EP treatment, adverse events of special interests were assessed. An AESI is an AE of scientific and medical interest specific to understanding of the IMP. AESIs for durvalumab include, but are not limited to, events with a potential inflammatory or immune-mediated mechanism and which may require more frequent monitoring and/or interventions such as steroids, immunosuppressants, and/or hormone replacement therapy. This includes adverse events of special/ possible interest.

Time frame:
From first dose of study treatment until 90 days after discontinuation, up to 2.5 years.
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events of Special Interests
ParticipantsDurvalumab+EP
Number of Participants With Adverse Events of Special Interests82

Adverse events

Collected over From first dose of study treatment until 90 days after treatment discontinuation, up to 2.5 years.. Non-serious events are listed at a 0.03% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Durvalumab+EP85/152 (55.9%)52/152 (34.2%)136/152 (89.5%)
Most frequent serious events
Showing 10 of 65
Most frequent serious events
EventDurvalumab+EP
PneumoniaInfections and infestations9/152
HyponatraemiaMetabolism and nutrition disorders4/152
Acute kidney injuryRenal and urinary disorders4/152
AnaemiaBlood and lymphatic system disorders3/152
LeukopeniaBlood and lymphatic system disorders3/152
HyperglycaemiaMetabolism and nutrition disorders3/152
Abdominal pain upperGastrointestinal disorders3/152
Platelet count decreasedInvestigations3/152
SepsisInfections and infestations2/152
Febrile neutropeniaBlood and lymphatic system disorders2/152
Most frequent other events
Showing 10 of 57
Most frequent other events
EventDurvalumab+EP
AnaemiaBlood and lymphatic system disorders85/152
NeutropeniaBlood and lymphatic system disorders51/152
NauseaGastrointestinal disorders37/152
ConstipationGastrointestinal disorders30/152
ThrombocytopeniaBlood and lymphatic system disorders24/152
FatigueGeneral disorders24/152
AlopeciaSkin and subcutaneous tissue disorders20/152
LeukopeniaBlood and lymphatic system disorders19/152
HypomagnesaemiaMetabolism and nutrition disorders19/152
HyperthyroidismEndocrine disorders18/152

Baseline characteristics

Safety analysis set (SAF) which consisted of all enrolled patients who received at least 1 dose of any study treatment.

Age, Continuous
Age, Continuous(Years)Durvalumab +EP
Median64.0 (27 to 83)
Sex: Female, Male
Sex: Female, Male(Participants)Durvalumab +EP
Female54
Male98
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Durvalumab +EP
White151
Other1
08

Study locations

35 sites
  • Research Site
    Panagyurishte, 4500, Bulgaria
  • Research Site
    Ruse, 7002, Bulgaria
  • Research Site
    Sofia, 1303, Bulgaria
  • Research Site
    Sofia, 1330, Bulgaria
  • Research Site
    Sofia, 1407, Bulgaria
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
  • Research Site
    Burgas, 180 81, Czechia
  • Research Site
    Olomouc, 779 00, Czechia
  • Research Site
    Ostrava, 703 00, Czechia
  • Research Site
    Berlin, 12351, Germany
  • Research Site
    Berlin, 13125, Germany
  • Research Site
    Gauting, 82131, Germany
  • Research Site
    Hamburg, 20251, Germany
  • Research Site
    Jena, 07747, Germany
  • Research Site
    Kassel, 34125, Germany
  • Research Site
    Köln, 51109, Germany
  • Research Site
    Ancona, 60126, Italy
  • Research Site
    Bari, 70124, Italy
  • Research Site
    Milano, 20141, Italy
  • Research Site
    Napoli, 80131, Italy
  • Research Site
    Orbassano, 10043, Italy
  • Research Site
    Palermo, 90146, Italy
  • Research Site
    Roma, 00168, Italy
  • Research Site
    Adapazari, 54290, Turkey
  • Research Site
    Ankara, 06010, Turkey
  • Research Site
    Ankara, 06100, Turkey
  • Research Site
    Ankara, 06800, Turkey
  • Research Site
    Antalya, 07070, Turkey
  • Research Site
    Bursa, 16059, Turkey
  • Research Site
    Edirne, 22030, Turkey
  • Research Site
    Istanbul, 34098, Turkey
  • Research Site
    Istanbul, 34722, Turkey
  • Research Site
    Izmir, 35100, Turkey
  • Research Site
    Malatya, 44280, Turkey
  • Research Site
    Pamukkale, 20070, Turkey
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Jun 2023, 19 months.

Results were first posted in Aug 2024, 1 year 2 months after primary completion.

Of 55 industry-sponsored phase 3 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 44. This study's 19 months is below that.

Counting every sponsor, half of 68 studies reached it within 41 months; a quarter within 31 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2021
First posted
Mar 1, 2021
StartActual
Nov 11, 2021
Primary completionActual
Jun 12, 2023
CompletionActual
Jan 2, 2025
Results first posted
Aug 20, 2024
Last update
May 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04774380
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 1, 2021
Start date
Nov 11, 2021
Primary completion
Jun 12, 2023
Completion
Jan 2, 2025
Results posted
Aug 20, 2024
Last update
May 23, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Etoposide

Start the discussion